RCKT Rocket Pharmaceuticals, Inc. Common Stock
XNAS
2.28
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
RCKT
$2.28
—
Key stats
$2.28
- 52-Week Range
- $2.17 – $5.45
- YTD
- -34.10%
- IV Rank (30D)
- 53.46
- Straddle Price
- $1.00
- P/C Vol Ratio
- 0.21
- Market Cap
- $0.3B
- Open
- $2.29
- Day Range
- $2.22 – $2.29
- Volume
- 1,514,758
- Prev Close
- $2.29
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 1.42 |
| Cost of Equity (CAPM) | 12.95% (VRP-adj) |
| WACC | 12.44% |
| Volatility Risk Premium | +141.3pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -4.7% |
| Book / Price | 143.2% — banking bias active (P/B is primary) |
| Debt / Equity | 0.05 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $3.06 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.44 |
| Bollinger Width / SMA20 | 1076.1% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$4.88
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 40.0× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.0× · 3 peers |
| Peer P/B | $11.38 | 22% | median 3.5× · 3 peers |
| Peer P/S | n/a | 0% | median 3.8× · 3 peers |
| Market Anchor (SMA50) | $3.06 | 78% | stability 70% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 202
- List Date
- 2015-02-18
- CIK
- 0001281895
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- ($0.39) (4 est.)
- Headquarters
- New York, NY
- Homepage
- https://www.rocketpharma.com
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -2.50% | -29.73% | 13.41% | -2.61% | -15.57% | 0.58% | -6.07% |
| Feb | -1.94% | 0.23% | -12.64% | 0.41% | -10.51% | 43.97% | 3.25% |
| Mar | -20.40% | -4.86% | -15.41% | -11.76% | -24.12% | -27.97% | -17.42% |
| Apr | 1.37% | -37.24% | 0.22% | -19.46% | 31.33% | -3.87% | -4.61% |
| May | -6.70% | 10.85% | 14.31% | -5.37% | -68.07% | -13.76% | -11.46% |
| Jun | 6.13% | 22.86% | -5.06% | -1.82% | -11.55% | 13.25% | 3.97% |
| Jul | -22.52% | 0.35% | -9.57% | 17.13% | 17.76% | -10.63% | -1.25% |
| Aug | -6.96% | 12.15% | -12.42% | -15.20% | 9.70% | 9.09% | -0.61% |
| Sep | -18.29% | 1.20% | 28.06% | 2.61% | 0.62% | -29.49% | -2.55% |
| Oct | -0.93% | 20.39% | -6.94% | -2.75% | 19.30% | -11.97%* | 2.85% |
| Nov | -21.14% | -0.63% | 22.79% | -15.25% | -3.93% | -- | -3.63% |
| Dec | -7.66% | 6.42% | 27.97% | -12.77% | 11.08% | -- | 5.01% |
| Total | -67.54% | -16.95% | 35.19% | -52.69% | -64.81% | -40.74% | -34.59% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.42
SMA 50: $3.04
SMA 200: $3.48
Current: $2.28
EMA 12: $2.35
EMA 26: $2.56
MACD: -0.2185 | Signal: 0.0242
BEARISH
ADX (14): 27.83
TREND
+DI: 12.84
−DI: 22.31
Momentum Oscillators
RSI (14): 37.60
NEUTRAL
Stoch %K: 20.87
Stoch %D: 18.88
Williams %R: -81.30
Volume & Volatility
BB Upper: $2.73
BB Lower: $2.10
NEUTRAL
OBV: -71,131,191
Vol SMA 20: 2,188,681
Vol ROC: -34.24%
ATR: $0.18
True Range: $0.07
HV 20: 66.3%
HV 30: 70.6%
HV 60: 66.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary BULLISH (Confidence Level: 7/10)
Key drivers:
- Bullish MACD signal
- Neutral RSI reading
- Supportive Bollinger Bands position
- Recent options activity suggests bullish sentiment
Primary risks:
- High volatility and beta value indicating potential for large price swings
- No recent news available, which could be a catalyst for price movement
Investment thesis: RCKT has the potential to trend higher in the short-term due to its bullish technical indicators and supportive market conditions. However, investors should be cautious of high volatility and the lack of recent news headlines.
Recent news sentiment impact: N/A (no recent news available)
Technical Analysis
- Trend Direction: Short-term bullish, Medium-term neutral, Long-term bearish
- Support/Resistance Levels: $3.23 (SMA 20), $2.96 (Lower Bollinger Band)
- Momentum Signals:
- RSI interpretation: Neutral at 55.20
- MACD signal: Bullish with a bullish crossover above the signal line
- Bollinger Bands position: Squeeze, indicating potential for price movement
- Volume Analysis: Volume rate of change indicates increasing volume
News & Sentiment Analysis
- Recent Headlines Summary: N/A (no recent news available)
- Sentiment Assessment: N/A (no recent news available)
- Catalyst Identification: No upcoming events or earnings releases scheduled
- Market Narrative: Bullish technical indicators and supportive market conditions
Risk & Volatility Assessment
- Beta Interpretation: High risk relative to the market with a beta value of 1.17
- Volatility Regime: Above-average volatility, indicating potential for large price swings
- Options Market Signals:
- IV rank: Low at 23.6%
- Put/call volume ratio: Bullish at 0.69
- Unusual activity: No unusual options activity detected
Market Context & Positioning
- Sector Performance: N/A (no sector information available)
- Institutional Activity: N/A (no institutional trading data available)
- Correlation Analysis: R-squared value of 0.22 indicates a moderate correlation with the market
- Relative Valuation: N/A (no relative valuation metrics available)
Key Levels & Action Items
- Critical Price Levels: $3.23 (SMA 20), $2.96 (Lower Bollinger Band)
- Breakout/Breakdown Levels: No specific levels detected, but watch for price movements above or below the Bollinger Bands
- Time-Sensitive Catalysts: Next earnings release on 2025-11-05
- Risk Management: Consider stop-loss levels at $2.96 (Lower Bollinger Band) and position sizing considerations
Generated
News
All RCKT news →
Earnings History
17 of 17 under expected move
Avg Expected Move
18.07%
Avg Actual Move
2.57%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-05-10 | Pre-Market | 5.14% | 0.96% | 0.19x | Within |
| 2021-08-09 | Pre-Market | 9.07% | 3.20% | 0.35x | Within |
| 2021-11-04 | Pre-Market | 13.06% | 3.83% | 0.29x | Within |
| 2022-02-24 | Pre-Market | 18.70% | 3.97% | 0.21x | Within |
| 2022-08-08 | Pre-Market | 18.44% | 1.80% | 0.10x | Within |
| 2022-11-03 | Pre-Market | 9.45% | 1.71% | 0.18x | Within |
| 2023-02-27 | Pre-Market | 13.78% | 1.76% | 0.13x | Within |
| 2024-02-26 | Pre-Market | 13.76% | 1.74% | 0.13x | Within |
| 2024-05-06 | Pre-Market | 17.30% | 1.15% | 0.07x | Within |
| 2024-08-05 | After-Close | 16.78% | 0.85% | 0.05x | Within |
| 2024-11-07 | Pre-Market | 22.04% | 1.88% | 0.09x | Within |
| 2025-02-27 | Pre-Market | 17.07% | 1.26% | 0.07x | Within |
| 2025-05-08 | Pre-Market | 22.39% | 5.07% | 0.23x | Within |
| 2025-08-07 | Pre-Market | 19.87% | 2.32% | 0.12x | Within |
| 2025-11-06 | Pre-Market | 36.14% | 2.71% | 0.07x | Within |
| 2026-02-26 | Pre-Market | 23.09% | 4.62% | 0.20x | Within |
| 2026-05-07 | Pre-Market | 31.09% | 4.92% | 0.16x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
RCKT Options Activity & IV Rank
RCKT IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 167.1%
7-DTE IV: —
Expected Move: $1.00
7-DTE Move: $1.00
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 42
Put Volume: 9
P/C Volume: 0.214
BULLISH
Call OI: 488
Put OI: 63
P/C OI: 0.129
Total OI: 551
ATM Options Pricing
ATM Call: $0.40
ATM Put: $0.60
Call %: 17.5%
Put %: 26.3%
Chain Summary
Chain Volume: 768
Chain OI: 4,643
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 51st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
51%
vs own history
GEX tilt
+0.83
OI-weighted, today
Vanna tilt
+0.87
δ-sensitivity to IV
Charm tilt
-0.76
δ-decay vs time
Vanna tilt +0.87: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.76: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 194.6% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)53.5MediumOct 26
Straddle Price (30 DTE)$1.00Oct 26
Beta Analysis
Risk Metrics
Beta: 1.7051
Alpha: -51.72%
Correlation: 0.3190
R-Squared: 10.2%
Stock Volatility: 68.1%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
RCKT Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 112,507,498 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$1.47M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $612.86K | 41.61% | 2026-06-30 |
| 2 | Goldman Sachs Group Inc Custodian | $478.80K | 32.50% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $222.30K | 15.09% | 2026-06-30 |
| 4 | Wolverine Trading, LLC Custodian | $159.08K | 10.80% | 2025-09-30 |
2 filers$143.09K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $98.15K | 68.60% | 2026-06-30 |
| 2 | Wolverine Trading, LLC Custodian | $44.94K | 31.40% | 2025-09-30 |
RCKT Insider Trading (Form 4)
Latest: 2026-09-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Martin Wilson | General Counsel | Sell (S) | −75,364 | $3.40 | -$256.5K | EDGAR |
| 2026-08-20 | Gaurav Shah | CEO | Sell (S) | −2,293 | $3.38 | -$7.8K | EDGAR |
| 2026-08-20 | Martin Wilson | General Counsel | Sell (S) | −631 | $3.38 | -$2.1K | EDGAR |
| 2026-08-17 | Martin Wilson | General Counsel | Sell (S) | −3,493 | $3.38 | -$11.8K | EDGAR |
| 2026-08-17 | Gaurav Shah | CEO | Sell (S) | −2,837 | $3.38 | -$9.6K | EDGAR |
| 2026-08-13 | Sarbani Chaudhuri | See Remarks | Sell (S) | −4,701 | $3.50 | -$16.4K | EDGAR |
| 2026-08-13 | Christopher James Stevens | Chief Operating Officer | Sell (S) | −36,658 | $3.50 | -$128.3K | EDGAR |
| 2026-08-05 | Christopher James Stevens | Chief Operating Officer | Award (A) | +73,313 | — | EDGAR | |
| 2026-08-05 | David P Southwell | Director | Other (J) | +150,000 | — | EDGAR | |
| 2026-07-06 | Mikael Dolsten | Director | Award (A) | +22,862 | — | EDGAR | |
| 2026-07-06 | Fady Ibraham Malik | Director | Award (A) | +22,862 | — | EDGAR | |
| 2026-07-06 | Carsten Boess | Director | Award (A) | +22,862 | — | EDGAR | |
| 2026-07-06 | Peter Fong | Director | Award (A) | +22,862 | — | EDGAR | |
| 2026-07-06 | David P Southwell | Director | Award (A) | +22,862 | — | EDGAR | |
| 2026-07-06 | Roderick Wong | Director | Award (A) | +27,832 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
RCKT Insider Holdings
10 insiders · @ $2.28
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Roderick Wong | Director | 18,263,956 | $41.64M | -$32.05M | 11 | 2026-07-06 |
| 2 | Gaurav Shah | CEO | 1,254,935 | $2.86M | -$1.15M | 16 | 2026-08-20 |
| 3 | Martin Wilson | General Counsel | 598,489 | $1.36M | -$270.4K | 6 | 2026-09-15 |
| 4 | Christopher James Stevens | Chief Operating Officer | 505,784 | $1.15M | -$128.3K | 2 | 2026-08-13 |
| 5 | David P Southwell | Director | 317,646 | $724.2K | -$1.46M | 9 | 2026-08-05 |
| 6 | Sarbani Chaudhuri | See Remarks | 262,809 | $599.2K | -$16.4K | 1 | 2026-08-13 |
| 7 | Peter Fong | Director | 76,195 | $173.7K | $0 | 1 | 2026-07-06 |
| 8 | Mikael Dolsten | Director | 67,082 | $152.9K | $0 | 1 | 2026-07-06 |
| 9 | Carsten Boess | Director | 52,862 | $120.5K | $0 | 6 | 2026-07-06 |
| 10 | Fady Ibraham Malik | Director | 52,862 | $120.5K | $0 | 3 | 2026-07-06 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
RCKT Board & Officers
As of SEC filings through Sep 15, 2026Directors 9
- David P Southwell · listed since Jun 2015
- Carsten Boess · since Jan 11, 2016
- Roderick Wong · since Jan 4, 2018
- Elisabeth Bjork · since Apr 20, 2020
- Fady Ibraham Malik · since Mar 10, 2022
- Rtw Investments, LP (entity) · listed since Aug 2023
- Mikael Dolsten · since Sep 5, 2024
- Piratip Pratumsuwan · since Jan 27, 2025
- Peter Fong · since Sep 24, 2025
Officers 8
- Gaurav Shah · CEO · listed since Apr 2021
- John Militello · Vice President of Finance, Treasurer, Principal Accounting Officer · listed since Apr 2024
- Christopher James Stevens · Chief Operating Officer · since Jul 7, 2025
- Jonathan David Schwartz · Chief Medical & Gene Therapy Officer · listed since Feb 2025
- Sarbani Chaudhuri · Chief Commercial & Medical Affairs Officer · since Apr 7, 2025
- Syed Ali-aamir Rizvi · Chief Medical Officer · since Sep 15, 2025
- Martin Wilson · General Counsel · since Dec 6, 2021
- Joseph Manhede · Principal Accounting Officer · since Jul 8, 2026
10% owners 2
- Roderick Wong · since Jan 4, 2018
- Rtw Investments, LP (entity) · listed since Apr 2023
Changes in the last 10 years (56)
| Jul 8, 2026 | Joseph Manhede became Principal Accounting Officer |
| Feb 13, 2026 | Gaurav Shah no longer listed as a director in SEC filings |
| Sep 29, 2025 | The company announced the departure of Pedro P Granadillo from the board in an SEC filing |
| Sep 24, 2025 | Peter Fong became a director |
| Sep 23, 2025 | The company announced the departure of Gotham Makker from the board in an SEC filing |
| Sep 15, 2025 | Syed Ali-aamir Rizvi became Chief Medical Officer |
| Aug 20, 2025 | The company announced the departure of Aaron Ondrey as Chief Financial Officer in an SEC filing |
| Jul 7, 2025 | The company announced the departure of Kinnari Patel as President, Head of R&D and Chief Operating Officer in an SEC filing |
| Jul 7, 2025 | Christopher James Stevens became Chief Operating Officer |
| Apr 7, 2025 | Sarbani Chaudhuri became Chief Commercial & Medical Affairs Officer |
| Feb 13, 2025 | Jonathan David Schwartz listed as Chief Medical & Gene Therapy Officer (previously Chief Medical Officer & Clinical Development, SVP) in SEC filings |
| Jan 27, 2025 | Piratip Pratumsuwan became a director |
| Jan 25, 2025 | The company announced the departure of Naveen Yalamanchi from the board in an SEC filing |
| Dec 2, 2024 | The company announced the departure of Mark Andrew White as General Manager, Commercial Affairs in an SEC filing |
| Sep 5, 2024 | Mikael Dolsten became a director |
| May 20, 2024 | Kinnari Patel listed as President, Head of R&D and Chief Operating Officer (previously President & Chief Operating Officer) in SEC filings |
| Apr 24, 2024 | John Militello listed as Vice President of Finance, Treasurer, Principal Accounting Officer (previously VP, Principal Accounting Officer and Interim Principal Financial Officer) in SEC filings |
| Apr 10, 2024 | Mark Andrew White listed as General Manager, Commercial Affairs (previously Chief Medical Officer) in SEC filings |
| Mar 25, 2024 | Aaron Ondrey became Chief Financial Officer |
| Dec 7, 2023 | The company announced the departure of Keith Woods from the board in an SEC filing |
| Dec 7, 2023 | Keith Woods became a director |
| Aug 30, 2023 | Rtw Investments, LP first listed as a director in an SEC filing |
| Apr 5, 2023 | Rtw Investments, LP first listed as a 10% owner in an SEC filing |
| Apr 4, 2023 | Mark Andrew White became Chief Medical Officer |
| Dec 23, 2022 | Rtw Investments, LP no longer listed as a director in SEC filings |
| Oct 11, 2022 | Rtw Investments, LP no longer listed as a 10% owner in SEC filings |
| Aug 16, 2022 | Kinnari Patel listed as President & Chief Operating Officer (previously Chief Operating Officer) in SEC filings |
| Jun 15, 2022 | Naveen Yalamanchi no longer listed as a 10% owner in SEC filings |
| Apr 20, 2022 | John Militello listed as VP, Principal Accounting Officer and Interim Principal Financial Officer (previously VP, Finance, Senior Controller and Treasurer) in SEC filings |
| Apr 1, 2022 | Jonathan David Schwartz listed as Chief Medical Officer & Clinical Development, SVP (previously Chief Medical Officer) in SEC filings |
| Mar 10, 2022 | The company announced the departure of Carlos Garcia-Parada as Chief Financial Officer in an SEC filing |
| Mar 10, 2022 | Fady Ibraham Malik became a director |
| Dec 6, 2021 | Martin Wilson became General Counsel |
| Aug 31, 2021 | Naveen Yalamanchi first listed as a 10% owner in an SEC filing |
| Apr 1, 2021 | Gaurav Shah listed as CEO (previously President & CEO) in SEC filings |
| Jan 4, 2021 | Carlos Garcia-Parada became Chief Financial Officer |
| Aug 5, 2020 | John Militello listed as VP, Finance, Senior Controller and Treasurer (previously Controller, Principal Financial Officer and Principal Accounting Officer) in SEC filings |
| Apr 20, 2020 | Elisabeth Bjork became a director |
| Oct 28, 2019 | Kamran Alam became SVP - Finance & PFO |
| Aug 29, 2018 | Rtw Investments, LP first listed as a director in an SEC filing |
| Apr 2, 2018 | David P Southwell no longer listed as President and CEO in SEC filings |
| Jan 25, 2018 | John Militello became Controller, Principal Financial Officer and Principal Accounting Officer |
| Jan 4, 2018 | Rtw Investments, LP became a 10% owner |
| Jan 4, 2018 | Roderick Wong became a director |
| Jan 4, 2018 | Roderick Wong became a 10% owner |
| Jan 4, 2018 | Pedro P Granadillo became a director |
| Jan 4, 2018 | Naveen Yalamanchi became a director |
| Jan 4, 2018 | Kinnari Patel became Chief Operating Officer |
| Jan 4, 2018 | Jonathan David Schwartz became Chief Medical Officer |
| Jan 4, 2018 | Gotham Makker became a director |
| Jan 4, 2018 | Gaurav Shah became a director |
| Jan 4, 2018 | Gaurav Shah became President & CEO |
| Jan 4, 2018 | Brian Batchelder became an officer |
| Jan 6, 2017 | Devon Park Bioventures LP reported in an SEC filing no longer being a 10% owner |
| Jan 6, 2017 | Devon Park Associates, LLC reported in an SEC filing no longer being a 10% owner |
| Jan 6, 2017 | Devon Park Associates, L.P. reported in an SEC filing no longer being a 10% owner |
Not reported recently (10)
- Kamran Alam · Last reported as SVP - Finance & PFO in an SEC filing dated Feb 10, 2020
- Brian Batchelder · Last reported as an officer in an SEC filing dated Jan 16, 2018
- Dale Ritter · Last reported as Vice President, Finance in an SEC filing dated Sep 18, 2017
- Paul G Howes · Last reported as a director in an SEC filing dated Jun 21, 2017
- Richard N. Spivey · Last reported as a director in an SEC filing dated Jun 21, 2017
- Gary M. Phillips · Last reported as a director in an SEC filing dated Jun 21, 2017
- J Martin Carroll · Last reported as a director in an SEC filing dated Jun 21, 2017
- Patrick Machado · Last reported as a director in an SEC filing dated Jun 21, 2017
- Timothy J Barberich · Last reported as a director in an SEC filing dated Jun 21, 2017
- Rudolf A Baumgartner · Last reported as Executive Vice President, Chief Medical Officer in an SEC filing dated Jan 24, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
RCKT Proposed Insider Sales (Form 144)
Latest: 2026-09-15
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
11 filings
· $513K notice value
· 5 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Wilson Martin (3, $270K) · Stevens Christopher James (1, $128K) · Militello John (4, $80K) · Shah Gaurav (2, $17K) · Chaudhuri Sarbani (1, $16K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-15 | Militello John | Former Officer | 6,897 | $22.7K | 2026-09-15 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-09-14 | Militello John | Former Officer | 6,857 | $22.7K | 2026-09-14 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-09-11 | Wilson Martin | Officer | 75,364 | $256.5K | 2026-09-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-09-11 | Militello John | Former Officer | 8,923 | $30.4K | 2026-09-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-18 | Shah Gaurav | Officer, Director | 2,293 | $7.8K | 2026-08-18 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-18 | Wilson Martin | Officer | 631 | $2.1K | 2026-08-18 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-18 | Militello John | Former Officer | 1,252 | $4.2K | 2026-08-18 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-13 | Wilson Martin | Officer | 3,493 | $11.8K | 2026-08-13 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-13 | Shah Gaurav | Officer, Director | 2,837 | $9.6K | 2026-08-13 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-11 | Stevens Christopher James | Officer | 36,658 | $128.3K | 2026-08-11 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
47 ETFs hold RCKT
25 shown · $32.71M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $7.1M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $5.3M | $74.6B | 2026-10-23 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.8M | — | 2026-09-30 |
| 4 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.03% | $2.3M | $6.6B | 2026-10-23 |
| 5 | GTO Invesco Total Return Bond ETF | Invesco | 0.06% | $1.9M | — | 2026-10-24 |
| 6 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $1.9M | $13.9B | 2026-10-23 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.02% | $1.9M | $10.7B | 2026-10-23 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.4M | — | 2026-09-30 |
| 9 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.3M | — | 2026-05-31 |
| 10 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $1.2M | — | 2026-10-23 |
| 11 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.04% | $1.0M | — | 2026-07-31 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $692,616 | — | 2026-09-30 |
| 13 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.05% | $626,276 | $1.2B | 2026-10-23 |
| 14 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.01% | $622,598 | — | 2026-10-23 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $382,018 | — | 2026-10-23 |
| 16 | FLXI Invesco Flexible Income ETF | Invesco | 2.66% | $361,898 | — | 2026-10-24 |
| 17 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.76% | $351,505 | — | 2026-07-31 |
| 18 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.01% | $296,956 | $3.2B | 2026-10-23 |
| 19 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $275,182 | $96.5B | 2026-10-23 |
| 20 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $218,869 | — | 2026-09-30 |
| 21 | GNOM Global X Genomics & Biotechnology ETF | Global X | 0.18% | $187,026 | — | 2026-10-26 |
| 22 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.06% | $160,125 | — | 2026-05-31 |
| 23 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $157,598 | — | 2026-05-31 |
| 24 | GTOC Invesco Core Fixed Income ETF | Invesco | 0.04% | $148,780 | — | 2026-10-24 |
| 25 | GTOS Invesco Short Duration Total Return Bond ETF | Invesco | 0.10% | $120,633 | — | 2026-10-24 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.17
TTM Revenue
—
TTM Net Income
$-17.25M
TTM Op. Cash Flow
$-170.27M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $123.21M | $1.08 | $-39.61M |
| Q1 '26 | 2026-03-31 | — | $-47.59M | $-0.42 | $-45.39M |
| Q4 '25 | 2025-12-31 | — | $-42.54M | $-0.38 | $-34.84M |
| Q3 '25 | 2025-09-30 | — | $-50.33M | $-0.45 | $-50.42M |
| Q2 '25 | 2025-06-30 | — | $-68.92M | $-0.62 | $-48.96M |
| Q1 '25 | 2025-03-31 | — | $-61.33M | $-0.56 | $-55.79M |
| Q4 '24 | 2024-12-31 | — | $-60.33M | $-0.62 | $-46.94M |
| Q3 '24 | 2024-09-30 | — | $-66.72M | $-0.71 | $-52.10M |
| Q2 '24 | 2024-06-30 | — | $-69.65M | $-0.74 | $-53.82M |
| Q1 '24 | 2024-03-31 | — | $-62.05M | $-0.66 | $-56.86M |
| Q4 '23 | 2023-12-31 | — | $-59.66M | $-0.62 | $-29.34M |
| Q3 '23 | 2023-09-30 | — | $-61.90M | $-0.75 | $-57.15M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.70
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-4.7%
ROA
-4.1%
Div Yield
0.00%
FCF Yield
-66.38%
Debt/Equity
0.05
Current Ratio
—
Market Cap
$256.52M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
15.05M
SI % of Float
17.79%
Days to Cover
6.94
Short Vol Ratio
61.3%
Free Float
84.59M
Float %
77.5%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-05-27